Ironwood Pharmaceuticals, Inc.  

(Public, NASDAQ:IRWD)   Watch this stock  
Find more results for IRWD
15.44
+0.34 (2.25%)
Mar 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.77 - 15.67
52 week 9.01 - 17.11
Open 14.98
Vol / Avg. 0.00/1.02M
Mkt cap 2.13B
P/E     -
Div/yield     -
EPS -1.39
Shares 124.92M
Beta 1.40
Inst. own 109%
Apr 27, 2015
Q1 2015 Ironwood Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 11, 2015
Ironwood Pharmaceuticals Inc at Barclays Healthcare Conference
Mar 2, 2015
Ironwood Pharmaceuticals Inc at Cowen Health Care Conference
Feb 12, 2015
Q4 2014 Ironwood Pharmaceuticals Inc Earnings Call - Webcast
Feb 12, 2015
Q4 2014 Ironwood Pharmaceuticals Inc Earnings Release
Jan 12, 2015
Ironwood Pharmaceuticals Inc at JPMorgan Healthcare Conference - Q&A Session
Jan 12, 2015
Ironwood Pharmaceuticals Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -98.88% -248.07%
Operating margin -87.00% -221.58%
EBITD margin - -205.45%
Return on average assets -44.43% -61.92%
Return on average equity -153.53% -299.14%
Employees 464 -
CDP Score - -

Address

301 Binney St
CAMBRIDGE, MA 02142-1030
United States - Map
+1-617-6217722 (Phone)
+1-617-4940480 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on creating medicines that make a difference for patients. The Company�s lead product, linaclotide provides patients and healthcare practitioners with a treatment option for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), GI disorders that affect millions of sufferers across the world. Linaclotide is available to adult men and women suffering from IBS-C, or CIC, in the United States under the trademarked name LINZESS, and to adult men and women suffering from IBS-C in the European Union (the E.U.), under the trademarked name CONSTELLA. The Company�s partner Astellas initiated a double-blind, placebo-controlled Phase III clinical trial of linaclotide in adult patients with IBS-C.

Officers and directors

Bryan E. Roberts Ph.D. Independent Chairman of the Board
Age: 47
Bio & Compensation  - Reuters
Peter M. Hecht Ph.D. Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Thomas Graney Chief Financial Officer, Senior Vice President - Finance, Corporate Strategy
Age: 50
Bio & Compensation  - Reuters
Mark G. Currie Ph.D. Senior Vice President, Chief Scientific Officer, President - Research and Development
Age: 60
Bio & Compensation  - Reuters
Thomas A. McCourt Senior Vice President - Marketing and Sales, Chief Commercial Officer
Age: 57
Bio & Compensation  - Reuters
Halley E. Gilbert Esq. Senior Vice President, Chief Legal Officer, Secretary
Age: 45
Bio & Compensation  - Reuters
Gina Consylman Chief Accounting Officer, Vice President, Corporate Controller
Age: 42
Bio & Compensation  - Reuters
Douglas E. Williams Ph.D. Director
Age: 56
Bio & Compensation  - Reuters
George H. Conrades Independent Director
Age: 75
Bio & Compensation  - Reuters
Joseph C. Cook Jr. Independent Director
Age: 72
Bio & Compensation  - Reuters